Ardelyx/ US0396971071 /
2024-04-24 9:59:58 PM | Chg. +0.05 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
6.43USD | +0.78% | 59,090 Turnover: 382,777.17 |
-Bid Size: - | -Ask Size: - | 6.64 | 6.39 |
GlobeNewswire
03-25
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate ...
GlobeNewswire
03-19
American Kidney Fund Launches Phosphorus Management Education and Awareness Campaign
GlobeNewswire
03-18
American Kidney Fund Convenes Nation’s Kidney Community for 2024 Kidney Action Week™ March 18-22
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
02-29
Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease
GlobeNewswire
02-22
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire
02-01
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
GlobeNewswire
01-08
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
GlobeNewswire
01-03
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Mo...
GlobeNewswire
2023-11-21
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
GlobeNewswire
2023-11-16
Jeremy Caldwell, Ph.D., Accomplished Biopharma Executive, Company Creator and R&D Leader, Joins Red ...
GlobeNewswire
2023-11-15
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hype...
GlobeNewswire
2023-11-03
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorp...